Hubei Biocause Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported revenue was CNY 41,188.01 million compared to CNY 37,829.6 million a year ago. Net loss was CNY 213 million compared to net income of CNY 237.61 million a year ago.

Basic loss per share from continuing operations was CNY 0.0431 compared to basic earnings per share from continuing operations of CNY 0.0481 a year ago. Diluted loss per share from continuing operations was CNY 0.0431 compared to diluted earnings per share from continuing operations of CNY 0.0481 a year ago.